Biotinylated Delta Variant Spike RBD SARS-CoV-2

Product Description

Biotinylated Delta Variant Spike RBD SARS-CoV-2  
Catalog number: B2010481
Lot number: Batch Dependent
Expiration Date: Batch dependent
Amount: 25 ug
Molecular Weight or Concentration: 27 kDa
Supplied as: Buffered Solution
Appearance: Solution
Applications: highly pure (> 95%) biotinylated SARS-CoV-2 RBD of the Delta Variant. This protein was expressed in HEK293, biotinylated in vitro and tested for its ability to bind the human cellular receptor ACE2.
Storage: -20C
Keywords: Biotin RBD, Biotin Delta RBD
Grade: Biotechnology grade. All solid components are highly pure (minimum 95%). All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um.

Download SARS-CoV-2 Brochure

References:
1: Bertoglio F, Fühner V, Ruschig M, Heine PA, Abassi L, Klünemann T, Rand U,
Meier D, Langreder N, Steinke S, Ballmann R, Schneider KT, Roth KDR, Kuhn P,
Riese P, Schäckermann D, Korn J, Koch A, Chaudhry MZ, Eschke K, Kim Y, Zock-
Emmenthal S, Becker M, Scholz M, Moreira GMSG, Wenzel EV, Russo G, Garritsen
HSP, Casu S, Gerstner A, Roth G, Adler J, Trimpert J, Hermann A, Schirrmann T,
Dübel S, Frenzel A, Van den Heuvel J, Čičin-Šain L, Schubert M, Hust M. A SARS-
CoV-2 neutralizing antibody selected from COVID-19 patients binds to the
ACE2-RBD interface and is tolerant to most known RBD mutations. Cell Rep. 2021
Jul 27;36(4):109433.

2: Shen X, Tang H, McDanal C, Wagh K, Fischer W, Theiler J, Yoon H, Li D, Haynes
BF, Sanders KO, Gnanakaran S, Hengartner N, Pajon R, Smith G, Glenn GM, Korber
B, Montefiori DC. SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing
antibodies elicited by ancestral spike vaccines. Cell Host Microbe. 2021 Apr
14;29(4):529-539.e3.

3: Ou J, Zhou Z, Dai R, Zhang J, Zhao S, Wu X, Lan W, Ren Y, Cui L, Lan Q, Lu L,
Seto D, Chodosh J, Wu J, Zhang G, Zhang Q. V367F Mutation in SARS-CoV-2 Spike
RBD Emerging during the Early Transmission Phase Enhances Viral Infectivity
through Increased Human ACE2 Receptor Binding Affinity. J Virol. 2021 Jul
26;95(16):e0061721.

4: Pymm P, Adair A, Chan LJ, Cooney JP, Mordant FL, Allison CC, Lopez E,
Haycroft ER, O’Neill MT, Tan LL, Dietrich MH, Drew D, Doerflinger M, Dengler MA,
Scott NE, Wheatley AK, Gherardin NA, Venugopal H, Cromer D, Davenport MP,
Pickering R, Godfrey DI, Purcell DFJ, Kent SJ, Chung AW, Subbarao K, Pellegrini
M, Glukhova A, Tham WH. Nanobody cocktails potently neutralize SARS-CoV-2 D614G
N501Y variant and protect mice. Proc Natl Acad Sci U S A. 2021 May
11;118(19):e2101918118.

5: Gobeil SM, Janowska K, McDowell S, Mansouri K, Parks R, Stalls V, Kopp MF,
Manne K, Saunders K, Edwards RJ, Haynes BF, Henderson RC, Acharya P. Effect of
natural mutations of SARS-CoV-2 on spike structure, conformation and
antigenicity. bioRxiv [Preprint]. 2021 Mar 15:2021.03.11.435037.

6: Khan A, Wei DQ, Kousar K, Abubaker J, Ahmad S, Ali J, Al-Mulla F, Ali SS,
Nizam-Uddin N, Mohammad Sayaf A, Mohammad A. Preliminary Structural Data
Revealed That the SARS-CoV-2 B.1.617 Variant’s RBD Binds to ACE2 Receptor
Stronger Than the Wild Type to Enhance the Infectivity. Chembiochem. 2021 Aug
17;22(16):2641-2649.

7: Tsai MS, Yang YH, Lin YS, Chang GH, Hsu CM, Yeh RA, Shu LH, Cheng YC, Liu HT,
Wu YH, Wu YH, Shen RC, Wu CY. GB-2 blocking the interaction between ACE2 and
wild type and mutation of spike protein of SARS-CoV-2. Biomed Pharmacother. 2021
Aug 5;142:112011.

8: Gobeil SM, Janowska K, McDowell S, Mansouri K, Parks R, Stalls V, Kopp MF,
Manne K, Li D, Wiehe K, Saunders KO, Edwards RJ, Korber B, Haynes BF, Henderson
R, Acharya P. Effect of natural mutations of SARS-CoV-2 on spike structure,
conformation, and antigenicity. Science. 2021 Aug 6;373(6555):eabi6226.

9: Deshpande A, Harris BD, Martinez-Sobrido L, Kobie JJ, Walter MR. Epitope
Classification and RBD Binding Properties of Neutralizing Antibodies Against
SARS-CoV-2 Variants of Concern. Front Immunol. 2021 Jun 4;12:691715.
10: McCallum M, Bassi J, De Marco A, Chen A, Walls AC, Di Iulio J, Tortorici MA,
Navarro MJ, Silacci-Fregni C, Saliba C, Sprouse KR, Agostini M, Pinto D, Culap
K, Bianchi S, Jaconi S, Cameroni E, Bowen JE, Tilles SW, Pizzuto MS, Guastalla
SB, Bona G, Pellanda AF, Garzoni C, Van Voorhis WC, Rosen LE, Snell G, Telenti
A, Virgin HW, Piccoli L, Corti D, Veesler D. SARS-CoV-2 immune evasion by the
B.1.427/B.1.429 variant of concern. Science. 2021 Aug 6;373(6555):648-654.

Products Related to Delta Variant SARS-CoV-2 Spike RBD Biotinylated : SARS-CoV-2